AssetMark Inc’s Sinovac Biotech, Ltd SVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-63
| Closed | – | – | 3940 |
|
|
2026
Q2 | $0 | Buy |
63
+37
| +142% | – | ﹤0.01% | 3689 |
|
|
2026
Q1 | $0 | Hold |
26
| – | – | ﹤0.01% | 3623 |
|
|
2025
Q4 | $0 | Buy |
26
+2
| +8% | – | ﹤0.01% | 3492 |
|
|
2025
Q3 | $0 | Hold |
24
| – | – | ﹤0.01% | 3279 |
|
|
2025
Q2 | $0 | Buy |
+24
| New | – | ﹤0.01% | 3151 |
|
|
2024
Q4 | – | Sell |
-21
| Closed | – | – | 2686 |
|
|
2024
Q3 | $0 | Buy |
21
+5
| +31% | – | ﹤0.01% | 2394 |
|
|
2024
Q2 | $0 | Buy |
16
+3
| +23% | – | ﹤0.01% | 2273 |
|
|
2024
Q1 | $0 | Hold |
13
| – | – | ﹤0.01% | 2169 |
|
|
2023
Q4 | $0 | Sell |
13
-1
| -7% | – | ﹤0.01% | 2033 |
|
|
2023
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 1831 |
|
|
2023
Q2 | $0 | Buy |
+14
| New | – | ﹤0.01% | 1717 |
|
|
2023
Q1 | – | Sell |
-14
| Closed | – | – | 1735 |
|
|
2022
Q4 | $0 | Hold |
14
| – | – | ﹤0.01% | 1690 |
|
|
2022
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 1662 |
|
|
2022
Q2 | $0 | Buy |
14
+4
| +40% | – | ﹤0.01% | 1737 |
|
|
2022
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 1808 |
|
|
2021
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 1681 |
|
|
2021
Q3 | $0 | Buy |
+10
| New | – | ﹤0.01% | 1564 |
|
|
2017
Q1 | – | Sell |
-39
| Closed | – | – | 1563 |
|
|
2016
Q4 | $0 | Buy |
+39
| New | +$235 | ﹤0.01% | 1481 |
|
Other funds holding SVA
AssetMark Inc's SVA Position: Q3 2026 in Review
AssetMark Inc sold out of Sinovac Biotech, Ltd (SVA) in Q3 2026, closing a stake of 63 shares.
AssetMark Inc first reported a position in SVA in Q4 2016 and held it in 18 quarters. The position peaked at $0 in Q2 2026. 2 funds tracked by Wall St. Rank hold SVA as of Q3 2026.
- AssetMark Inc reported no remaining Sinovac Biotech, Ltd position as of Q3 2026 after selling out during the quarter.
- AssetMark Inc sold 63 Sinovac Biotech, Ltd shares in Q3 2026.
- AssetMark Inc first reported a position in Sinovac Biotech, Ltd in Q4 2016 and held it in 18 quarters.
- AssetMark Inc's Sinovac Biotech, Ltd position peaked at $0 in Q2 2026.
- 2 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2026.
Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.